Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Area of interest

Area of interest

Type (1 selected)

Type

Guidance programme

Showing 901 to 950 of 1904

Published guidance, NICE advice and quality standards
TitleReference numberPublishedLast updated
Decitabine for untreated acute myeloid leukaemia (terminated appraisal)TA548
Denosumab for preventing skeletal-related events in multiple myeloma (terminated appraisal)TA549
Post-traumatic stress disorderNG116
Chronic obstructive pulmonary disease (acute exacerbation): antimicrobial prescribingNG114
Tofacitinib for moderately to severely active ulcerative colitisTA547
Transcranial MRI-guided focused ultrasound thalamotomy for neuropathic painIPG632
Percutaneous insertion of a temporary heart pump for left ventricular haemodynamic support in high-risk percutaneous coronary interventionsIPG633
Urinary tract infection (catheter-associated): antimicrobial prescribingNG113
Padeliporfin for untreated localised prostate cancerTA546
Gemtuzumab ozogamicin for untreated acute myeloid leukaemiaTA545
Subcutaneous automated low-flow pump implantation for refractory ascites caused by cirrhosisIPG631
Selective internal radiation therapy for unresectable primary intrahepatic cholangiocarcinomaIPG630
Urinary tract infection (lower): antimicrobial prescribingNG109
Prostatitis (acute): antimicrobial prescribingNG110
Pyelonephritis (acute): antimicrobial prescribingNG111
Urinary tract infection (recurrent): antimicrobial prescribingNG112
Eltrombopag for treating chronic immune thrombocytopeniaTA293
Romiplostim for the treatment of chronic immune thrombocytopeniaTA221
Myeloma: diagnosis and managementNG35
Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanomaTA544
Lyme diseaseNG95
Tofacitinib for treating active psoriatic arthritis after inadequate response to DMARDsTA543
Renal replacement therapy and conservative managementNG107
Decision-making and mental capacityNG108
Cabozantinib for untreated advanced renal cell carcinomaTA542
E‑vita open plus for treating complex aneurysms and dissections of the thoracic aortaMTG16
Inotuzumab ozogamicin for treating relapsed or refractory B-cell acute lymphoblastic leukaemiaTA541
Intravesical microwave hyperthermia and chemotherapy for non-muscle-invasive bladder cancerIPG628
Chronic heart failure in adults: diagnosis and managementNG106
Preventing suicide in community and custodial settingsNG105
Lutetium (177Lu) oxodotreotide for treating unresectable or metastatic neuroendocrine tumoursTA539
Leadless cardiac pacemaker implantation for bradyarrhythmiasIPG626
Superior rectal artery embolisation for haemorrhoidsIPG627
Dinutuximab beta for treating neuroblastomaTA538
Sutureless aortic valve replacement for aortic stenosisIPG624
Flu vaccination: increasing uptakeNG103
Transurethral water vapour ablation for lower urinary tract symptoms caused by benign prostatic hyperplasiaIPG625
Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodineTA535
Alectinib for untreated ALK-positive advanced non-small-cell lung cancerTA536
Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDsTA537
Community pharmacies: promoting health and wellbeingNG102
Dupilumab for treating moderate to severe atopic dermatitisTA534
Low-intensity pulsed ultrasound to promote healing of fresh fractures at low risk of non-healingIPG621
Low-intensity pulsed ultrasound to promote healing of fresh fractures at high risk of non-healingIPG622
Low-intensity pulsed ultrasound to promote healing of delayed-union and non-union fracturesIPG623
Ocrelizumab for treating relapsing–remitting multiple sclerosisTA533
Superior capsular augmentation for massive rotator cuff tearsIPG619
Transaxial interbody lumbosacral fusion for severe chronic low back painIPG620
Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancerTA531
Crizotinib for treating ROS1-positive advanced non-small-cell lung cancerTA529

Results per page

  1. 10
  2. 25
  3. 50
  4. All